What is the latest ACUTAAS stock price?
The latest stored price for ACUTAAS is Rs 3,169.00 as of 2026-08-21.
gimli
ACUTAAS stock AI analysis
ACUTAAS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ACUTAAS CHEMICALS LIMITED is a small-cap stock in Healthcare. This Gimli page shows the latest available ACUTAAS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹3,169.00
1W return
-2.06%
1M return
-13.82%
3M return
+5.62%
6M return
+50.44%
1Y return
+126.26%
Market cap
₹25,944.95 cr
PE
66.81
PB
19.65
ROE
+38.78%
ROCE
+22.45%
RSI
44.49
Turnover
₹69.94 cr
Why it can matter in screens
- Momentum: ACUTAAS is below 50DMA, above 200DMA; RSI is 44.49.
- Returns: 1D -1.29%, 1W -2.06%, 1M -13.82%, 3M +5.62%, 1Y +126.26%.
- Trend levels: 52W high ₹3,740.00, 52W low ₹2,902.00, off high -15.27%.
- Liquidity: latest turnover is ₹69.94 cr; volume vs 20D is +0.64%.
- Valuation/profitability: PE 66.81, PB 19.65, ROE +38.78%, ROCE +22.45%.
- Growth: 3Y sales CAGR +24.34%, 3Y profit CAGR +30.17%.
Quick Answers
Is ACUTAAS above its 50DMA and 200DMA?
ACUTAAS is below 50DMA, above 200DMA. The latest 50DMA is 3,342.38 and the latest 200DMA is 2,450.21.
What are ACUTAAS PE, ROE and ROCE?
ACUTAAS has PE 66.81, ROE +38.78%, and ROCE +22.45% in Gimli's latest available snapshot.
How has ACUTAAS performed recently?
ACUTAAS has returned -13.82% over 1 month, +5.62% over 3 months, and +126.26% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 329.67 cr | 114.87 cr | 74.26 cr | 9.07 |
| 2026-03-31 | 443.86 cr | 194.62 cr | 134.28 cr | 16.04 |
| 2025-12-31 | 393.18 cr | 155.35 cr | 107.96 cr | 13.19 |
| 2025-09-30 | 316.04 cr | 105.16 cr | 71.86 cr | 8.82 |
| 2025-06-30 | 207.24 cr | 66.84 cr | 44.29 cr | 5.41 |
| 2025-03-31 | 301.57 cr | 90.74 cr | 62.48 cr | nan |
| 2024-12-31 | 274.99 cr | 70.34 cr | 44.95 cr | 5.68 |
| 2024-09-30 | 246.73 cr | 57.37 cr | 37.57 cr | 4.69 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2025-03-31 | 999.97 cr | 249.00 cr | 158.71 cr | 19.81 |
| 2024-03-31 | 713.01 cr | 103.90 cr | 42.77 cr | 5.83 |
| 2023-03-31 | 613.06 cr | 126.93 cr | 83.29 cr | 11.43 |
| 2022-03-31 | 520.13 cr | 107.94 cr | 71.95 cr | 10.52 |
| 2021-03-31 | n/a | n/a | n/a | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2025-03-31 | 1,549.26 cr | 185.22 cr | 12.94 cr | 1,320.08 cr |
| 2024-03-31 | 1,095.90 cr | 29.70 cr | 216.65 cr | 682.76 cr |
| 2023-03-31 | 766.94 cr | 30.53 cr | 3.60 cr | 593.96 cr |
| 2022-03-31 | 658.88 cr | 10.30 cr | 0.84 cr | 522.27 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2025-03-31 | 118.34 cr | -76.30 cr | n/a |
| 2024-03-31 | 125.17 cr | -189.51 cr | n/a |
| 2023-03-31 | 65.53 cr | -30.87 cr | n/a |
| 2022-03-31 | -11.93 cr | -45.69 cr | n/a |
| 2021-03-31 | n/a | n/a | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +32.66% | +21.61% | +19.56% | +14.17% | +26.16% | +0.00% |
| 2026-03-31 | +32.66% | +19.48% | +19.60% | +13.86% | +28.24% | +0.00% |
| 2025-12-31 | +32.66% | +16.67% | +21.70% | +15.11% | +28.96% | +0.00% |
| 2025-09-30 | +32.66% | +16.85% | +22.59% | +15.81% | +27.89% | +0.00% |
| 2025-06-30 | +32.66% | +16.94% | +22.38% | +16.27% | +28.01% | +0.00% |
| 2025-03-31 | +35.96% | +16.48% | +18.31% | +13.02% | +29.23% | +0.00% |
| 2024-12-31 | +35.96% | +15.52% | +20.24% | +13.68% | +28.27% | +0.00% |
| 2024-09-30 | +35.97% | +13.87% | +19.93% | +13.07% | +30.23% | +0.00% |
| 2024-06-30 | +35.98% | +12.92% | +14.81% | +8.61% | +36.29% | +0.00% |
| 2024-06-21 | +35.98% | +13.14% | +14.00% | +8.56% | +36.87% | +0.00% |
| 2024-05-31 | +39.07% | +10.01% | +8.81% | +5.18% | +42.12% | +0.00% |
| 2024-03-31 | +39.91% | +8.97% | +6.81% | +3.92% | +44.31% | +0.00% |
| 2023-12-31 | +39.91% | +11.65% | +7.58% | +5.44% | +40.86% | +0.00% |
| 2023-09-30 | +38.93% | +7.16% | +5.94% | +4.44% | +47.97% | +0.00% |
| 2023-06-30 | +39.41% | +6.73% | +5.23% | +4.49% | +48.63% | +0.00% |
| 2023-03-31 | +39.41% | +6.36% | +3.64% | +3.41% | +50.60% | +0.00% |
| 2022-12-31 | +39.41% | +6.41% | +3.72% | +3.31% | +50.46% | +0.00% |
| 2022-09-30 | +39.41% | +5.76% | +3.61% | +2.75% | +51.22% | +0.00% |
| 2022-06-30 | +41.05% | +0.00% | +6.04% | n/a | n/a | +0.00% |
| 2022-03-31 | +41.05% | +0.00% | +7.86% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 456,449.49 cr | 37.677543 | +15.50% | +15.99% |
| DIVISLAB | DIVI S LABORATORIES LTD | 228,223.36 cr | 78.319614 | +18.37% | +42.62% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 165,719.79 cr | 75.983398 | +17.33% | +34.25% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 124,992.04 cr | 63.823550 | +21.03% | +9.67% |
| CIPLA | CIPLA LTD | 115,693.19 cr | 34.304976 | +10.25% | -10.08% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,698.21 cr | 22.474914 | +17.93% | +13.61% |
| LUPIN | LUPIN LIMITED | 100,669.80 cr | 14.727517 | +34.34% | +12.19% |
| MANKIND | MANKIND PHARMA LIMITED | 98,418.27 cr | 47.977550 | +13.18% | -8.31% |
Try these prompts
- Analyze ACUTAAS CHEMICALS with valuation, momentum and industry peers
- Compare ACUTAAS with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare ACUTAAS with other Healthcare stocks
Data snapshot: 2026-08-21. Not investment advice.